Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Expenses: 2017-2024

Historic Accumulated Expenses for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $20.3 million.

  • Aclaris Therapeutics' Accumulated Expenses rose 107.20% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 107.20%. This contributed to the annual value of $20.3 million for FY2024, which is 4.56% up from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Accumulated Expenses is $20.3 million, which was up 4.56% from $19.4 million recorded in FY2023.
  • Over the past 5 years, Aclaris Therapeutics' Accumulated Expenses peaked at $20.3 million during FY2024, and registered a low of $5.9 million during FY2020.
  • In the last 3 years, Aclaris Therapeutics' Accumulated Expenses had a median value of $19.4 million in 2023 and averaged $16.2 million.
  • In the last 5 years, Aclaris Therapeutics' Accumulated Expenses decreased by 23.51% in 2020 and then surged by 123.49% in 2023.
  • Aclaris Therapeutics' Accumulated Expenses (Yearly) stood at $5.9 million in 2020, then skyrocketed by 70.18% to $10.1 million in 2021, then fell by 13.43% to $8.7 million in 2022, then surged by 123.49% to $19.4 million in 2023, then rose by 4.56% to $20.3 million in 2024.